Study of Matrix Gla Protein G-7A and T-138C Gene Polymorphisms in Patients with Type 2 Diabetes Mellitus

Yıl 2015, Cilt: 2 Sayı: 5, 283 - 87, 06.07.2015

Fulya Yukcu , Tammam Sipahi , Sibel Guldiken Serhat Huseyin Betul Ekiz Bilir

Öz

Objective: Type 2 diabetes mellitus is a major risk factor for aortic calcifications and cardiovascular disease (CVD).  Matrix Gla proteins (MGP) have a significant role in control of the process of calcification. The purpose of this study was to investigate the role of MGP G-7A and T-138C gene polymorphisms in development of aortic calcification and CVD in patients with type 2 diabetes mellitus.

Material and Methods: The study included 120 patients with type 2 diabetes mellitus and 134 control group. The MGP G-7A and T-138C gene polymorphisms were identified using polymerase chain reaction (PCR) and followed by restriction fragment length polymorphism (RFLP) methods.

Results: The G-7A genotype distribution in patients with type 2 diabetes mellitus AA=10.8%, GA=41.7% and GG=47.5% did not significantly differ from those in control group AA=15.7%, GA=48.5% and GG=35.8% (P=0.146). The T-138C genotype distribution in patients with type 2 diabetes mellitus CC=8.4%, CT=40.8% and TT=50.8% were also not significantly different from those in control group CC=3.7%, CT=39.6% and TT=56.7% (P=0.259). On the other hand; age, fasting blood glucose (FBG), cholesterol, high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) as expected were significantly differed between the patient-control groups (p<0.05).

Conclusion: This patient-control study show that G-7A and T-138C gene polymorphisms of MGP are not genetic risk factors for type 2 diabetes mellitus.

 

Anahtar Kelimeler

MGP, G-7A gene polymorphism, RFLP, T-138C gen polymorphism; Type 2 diabetes mellitus.

Study of Matrix Gla Protein G-7A and T-138C Gene Polymorphisms in Patients with Type 2 Diabetes Mellitus

Öz

Kaynakça

• Nowotny K, Jung T, Höhn A, Weber D, Grune T. Advanced Glycation End Products and Oxidative Stress in Type 2 Diabetes Mellitus. Biomolecules 2015;5:194-222.
• Esen B, Daşdemir S, Çinçin Z, Özdemircan A, Çakmakoğlu B. The Analysis Of Osteoprotegerin (Opg) Protein T950c Gene Polymorphism in Diabetes. İ. Ü. Deneysel Tıp Araştırma Enstitüsü Dergisi. 2011;l(1):40-46.
• Metabolik Kemik Hastalıkları. Türkiye Endokrinoloji ve Metabolizma Derneği Dergisi. 2013;19
• Tunon-Le Poultel D, Cannata-Andia J. B, Roman-Garcia P, et al. Association of matrix Gla protein gene functional polymorphisms with loss of bone mineral density and progression of aortic calcification. Osteoporos Int 2014;25: 1237–1246.
• Yoshikawa K, Abe H, Tominaga T, et al. Polymorphism in the human matrix Gla protein gene is associated with the progression of vascular calcification in maintenance hemodialysis patients. Clin Exp Nephrol 2013;17:882–889.
• Andrea E. Cassidy B, Lawrence F, et al. Matrix Gla Protein Gene Polymorphism Is Associated With Increased Coronary Artery Calcification Progression. Arterioscler Thromb Vasc Biol. 2013;33:645-651.
• Najafi M, Roustazadeh A, Amirfarhangi A, Kazemi B. Matrix Gla protein (MGP) promoter polymorphic variants and its serum level in stenosis of coronary artery. Mol Biol Rep 2014;41:1779–1786.
• Farzaneh-Far A, Davies J.D, Braam L, et al. A Polymorphism of th Human Matrix _-Carboxyglutamic Acid Protein Promoter Alters Binding of an Activating Protein-1 Complex and Is Associated with Altered Transcription and Serum Levels. The Journal Of Bıologıcal Chemıstry © 2001 by The American Society for Biochemistry and Molecular Biology, Inc. 2001;276(35),32466–32473.
• Keshavarz P, Inoue H, Sakamoto Y, et al. No evidence for association of the ENPP1 (PC-1) K121Q variant with risk of type 2 diabetes in a Japanese population. J Hum Genet 2006;51:559–566.
• Keskin Ö. Diabetes Mellitus ve Kardiyovasküler Komplikasyonlar. Kafkas J Med Sci 2011;1(2):81–85.
• Emral R. Diyabetik Hastalardaki Kardiyovasküler Etkilenimler. Türk Farmakoloji Derneği 21. Ulusal Farmakoloji Kongresi Bildiri Özet Kitabı. 2011;40-42.
• Demer L.L, Tintut Y. Vascular Calcification Pathobiology of a Multifaceted Disease. Circulation. 2008;117:2938-2948.
• Liabeuf S, Olivier B, Vemeer C, et al. Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein. Liabeuf et al. Cardiovascular Diabetology 2014;13-85.
• Tavridou A, Petridis I, Vasileiadis M. Association of VKORC1 S1639 G > A polymorphism with carotid intima–media thickness in type 2 diabetes mellitus. Diabetes Research and Clinical Practice 2011;94:236-241.
• Wang Y, Chen J,Zhang Y, et al. Common Genetic Variants of MGP Are Associated With Calcification on the Arterial Wall but Not With Calcification Present in the Atherosclerotic Plaques. Circ Cardiovasc Genet. 2013;6:271-278.
• Herrmann S.M, Whatling C, Brand E, et al. Polymorphisms of the Human Matrix Gla Protein (MGP) Gene, Vascular Calcification, and Myocardial Infarction. Arterioscler Thromb Vasc Biol. 2000;20:2386-2393.
• Garbusova V.Y, Gurianova V.L, Stroy D. A, et al. Allelic polymorphism of matrix Gla promoter G–7→A, but not T–138→C nor exon 4 Thr83→Ala, is positively associated with acute coronary syndrome in the Ukrainian population. Exp Clin Cardiol 2012;17(1):30-33.
• Ataman A. V, Garbusova V. Y, Ataman Y. A, et al. Investigation of the MGP promoter and exon 4 polymorphisms in patients with ischemic stroke in the Ukrainian population. Journal of Cell and Molecular Biology 2012;10(1):19-26.
• Crosier M. D, Booth S. L, Peter I, et al. Matrix Gla Protein Are Associated with Coronary Artery Calcification in Men. J Nutr Sci Vitaminol, 2009;55:59-65.